Medherant is a leading developer of next-generation transdermal drug delivery patches.
Transdermal delivery of drugs from a patch provides better control of the dose than achieved with gels, ointments and creams. However, the currently available technologies limit the types of drugs that can be used and the quantities that can be loaded into the patch. Medherant’s TEPI Patch® is formulated with a novel polymer adhesive that is mixed with the drug.
One of the key advantages of the TEPI Patch® technology is that a greater quantity of drug can be blended with the adhesive. This enables lower potency drugs to be formulated as a patch and provides the opportunity to increase the dose of drugs already administered via a patch. The TEPI Patch® also provides a better experience for the user as it does not leave a residue around the patch – referred to as ‘cold flow’ – and has excellent adhesion whilst still being easy and painless to remove.
Medherant is developing its own TEPI Patch® products and working with third parties to assess the suitability of the technology for their drugs.
The Company expects to earn revenues from licensing both its products and its technology for use with specific drugs.
Dr Andrew LeeDirector of Commercial Development
Mr Nigel DavisCEO
Microbiotica was launched in December 2016 with the aim of creating a global leader to exploit the leading microbiome science built at the Wellcome Trust Sanger Institute. The company retains a close association with the Sanger Institute and its founders and is based at the Wellcome Genome Campus, Cambridge UK.
Dr Nigel CrockettHead Business Development
MicroMatrices offers services and technologies to facilitate smarter compound selection and de-risk drug development by resolving targets that might not be detected with currently available platforms. We specialise in multiparameter analytics for in vitro 3D cell cultures, known to be more predictive and human-relevant than 2D cultures.
Our SpheroMatrices® (patent pending) enhanced analytics for 3D cell cultures, a spheroid tissue microarray technology, can be used to assess complex responses earlier in development to weed out compounds that might cause issues further down the pipeline.
We use a suite of pathology-guided molecular toxicological approaches in combination with innovative visualisation/localisation technologies which can add significantly enhanced resolving power to standard in vitro assays.
We can also adopt these approaches to FFPE tissues from in vivo studies, a cost and time effective method which unlocks the potential of these tissues for investigating mechanisms of toxicity and improving predictive capability.
Since 2011, MicroMatrices innovative and collaborative investigations have produced valuable information, saving time and money, for our clients in the areas of Early Discovery, Preclinical Safety & Efficacy, Toxicology, Biomarker Discovery and Investigative Toxicology.
We look forward to meeting Pharma companies and CROs to discuss areas of mutual interest in Berlin.
Dr Simon PlummerManaging Director
Mironid Limited is an innovative new drug discovery company that develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. This allows us to access multiple therapeutic areas for exploitation. Our current drug discovery pipeline is aimed at developing novel treatments for degenerative kidney diseases, chronic inflammatory diseases and cancer.